Immune-related Adverse Events with Immune Checkpoint Inhibitors in Thoracic Malignancies: Focusing on Non-small Cell Lung Cancer Patients

Overview

Journal J Thorac Dis

Publisher AME Publishing Company

Specialty Pulmonary Medicine

Date 2018 Jun 29

PMID 29951303

Citations 37

Authors

Jordi Remon

Laura Mezquita

Jesus Corral

Noelia Vilarino

Noemi Reguart

Affiliations

Soon will be listed here.

Abstract

Immune checkpoint inhibitors (ICIs) have revolutionized treatment landscape among non-small cell lung cancer (NSCLC) patients in first- and second-line setting, and may become soon new treatment options in other thoracic malignancies such as small cell lung cancer (SCLC) or mesothelioma. The use of these drugs has indubitably changed the toxicity profile the oncologists are familiar with, and new spectra of immune-related adverse events are being reported with the widespread use of immunotherapies in solid tumors. Clinical management and understanding of immune-related adverse events is new and complex but expertise is still limited. In this review, we are summarizing the incidence and management of main side effects related to ICIs focusing on NSCLC patients.

Citing Articles

Lichenoid drug reaction after ipilimumab/nivolumab combination therapy: A case report.

Moore Z, Zajdman-Faitelson D, Campillo A, Brito Bustillos D, Toussaint-Caire S, Berumen-Glinz C SAGE Open Med Case Rep. 2023; 11:2050313X231213927.

PMID: 38130914 PMC: 10734355. DOI: 10.1177/2050313X231213927.

An assessment of extended pembrolizumab dosing in advanced non-small-cell lung cancer in the COVID-19 pandemic.

Moffat G, Hanna L, Hopman W, Fung A, Gaudreau P Immunotherapy. 2023; 15(12):921-932.

PMID: 37431608 PMC: 10340130. DOI: 10.2217/imt-2022-0257.

Predicting response and toxicity to immune checkpoint inhibitors in lung cancer using antibodies to frameshift neoantigens.

Shen L, Brown J, Johnston S, Altan M, Sykes K J Transl Med. 2023; 21(1):338.

PMID: 37217961 PMC: 10201711. DOI: 10.1186/s12967-023-04172-w.

Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapy.

Sayer M, Mambetsariev I, Lu K, Wong C, Duche A, Beuttler R Front Oncol. 2023; 13:1064169.

PMID: 36860308 PMC: 9968834. DOI: 10.3389/fonc.2023.1064169.

Immune Checkpoint Inhibitors Induced Hepatotoxicity; Gastroenterologists' Perspectives.

Farshidpour M, Hutson W Middle East J Dig Dis. 2023; 14(2):244-253.

PMID: 36619143 PMC: 9489307. DOI: 10.34172/mejdd.2022.279.

References

Ott P, Elez E, Hiret S, Kim D, Morosky A, Saraf S . Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study. J Clin Oncol. 2017; 35(34):3823-3829. DOI: 10.1200/JCO.2017.72.5069. View

Peters S, Gettinger S, Johnson M, Janne P, Garassino M, Christoph D . Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). J Clin Oncol. 2017; 35(24):2781-2789. PMC: 5562171. DOI: 10.1200/JCO.2016.71.9476. View

Khunger M, Rakshit S, Pasupuleti V, Hernandez A, Mazzone P, Stevenson J . Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials. Chest. 2017; 152(2):271-281. DOI: 10.1016/j.chest.2017.04.177. View

Makarious D, Horwood K, Coward J . Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors. Eur J Cancer. 2017; 82:128-136. DOI: 10.1016/j.ejca.2017.05.041. View

Cortazar F, Marrone K, Troxell M, Ralto K, Hoenig M, Brahmer J . Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors. Kidney Int. 2016; 90(3):638-47. PMC: 4983464. DOI: 10.1016/j.kint.2016.04.008. View

Lee C, Man J, Lord S, Cooper W, Links M, Gebski V . Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non-Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis. JAMA Oncol. 2017; 4(2):210-216. PMC: 5838598. DOI: 10.1001/jamaoncol.2017.4427. View

Fujimoto D, Morimoto T, Ito J, Sato Y, Ito M, Teraoka S . A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia. Lung Cancer. 2017; 111:1-5. DOI: 10.1016/j.lungcan.2017.06.008. View

Kushnir I, Wolf I . Nivolumab-Induced Pericardial Tamponade: A Case Report and Discussion. Cardiology. 2016; 136(1):49-51. DOI: 10.1159/000447053. View

Leonardi G, Gainor J, Altan M, Kravets S, Dahlberg S, Gedmintas L . Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders. J Clin Oncol. 2018; 36(19):1905-1912. PMC: 6553840. DOI: 10.1200/JCO.2017.77.0305. View

10.

Chen Y, Liu F, Hsu C, Chian C . Nivolumab-induced myasthenia gravis in a patient with squamous cell lung carcinoma: Case report. Medicine (Baltimore). 2017; 96(27):e7350. PMC: 5502156. DOI: 10.1097/MD.0000000000007350. View

11.

Belum V, Benhuri B, Postow M, Hellmann M, Lesokhin A, Segal N . Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer. 2016; 60:12-25. PMC: 4998047. DOI: 10.1016/j.ejca.2016.02.010. View

12.

Nishino M, Hatabu H, Hodi F, Ramaiya N . Drug-Related Pneumonitis in the Era of Precision Cancer Therapy. JCO Precis Oncol. 2020; 1. PMC: 7446404. DOI: 10.1200/PO.17.00026. View

13.

Nishijima T, Muss H, Shachar S, Moschos S . Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis. Cancer Treat Rev. 2016; 45:30-7. DOI: 10.1016/j.ctrv.2016.02.006. View

14.

Hua C, Boussemart L, Mateus C, Routier E, Boutros C, Cazenave H . Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab. JAMA Dermatol. 2015; 152(1):45-51. DOI: 10.1001/jamadermatol.2015.2707. View

15.

Antonia S, Villegas A, Daniel D, Vicente D, Murakami S, Hui R . Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 377(20):1919-1929. DOI: 10.1056/NEJMoa1709937. View

16.

Goldstein D, Gordon N, Davidescu M, Leshno M, Steuer C, Patel N . A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non-Small Cell Lung Cancer. J Natl Cancer Inst. 2017; 109(11). DOI: 10.1093/jnci/djx063. View

17.

Antonia S, Lopez-Martin J, Bendell J, Ott P, Taylor M, Eder J . Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncol. 2016; 17(7):883-895. DOI: 10.1016/S1470-2045(16)30098-5. View

18.

Rossi E, Sgambato A, De Chiara G, Casaluce F, Losanno T, Sacco P . Endocrinopathies induced by immune-checkpoint inhibitors in advanced non-small cell lung cancer. Expert Rev Clin Pharmacol. 2015; 9(3):419-28. DOI: 10.1586/17512433.2016.1133289. View

19.

Shoushtari A, Friedman C, Navid-Azarbaijani P, Postow M, Callahan M, Momtaz P . Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in Melanoma. JAMA Oncol. 2017; 4(1):98-101. PMC: 5833656. DOI: 10.1001/jamaoncol.2017.2391. View

20.

Hellmann M, Rizvi N, Goldman J, Gettinger S, Borghaei H, Brahmer J . Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 2016; 18(1):31-41. PMC: 5476941. DOI: 10.1016/S1470-2045(16)30624-6. View